3D Bioprinting Market Segmented By 3D Bioprinters, Bioinks Component for Research and Clinical Applications
Industry: Healthcare
Published Date: September-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP3255
The global 3D bioprinting market is valued at US$ 1.9 Bn in 2022 and is anticipated to grow to a valuation of US$ 8 Bn by the end of 2032. The market is estimated to expand at a CAGR of 15% during the forecast period of 2022 to 2032.
In 2021, 3D bioprinters accounted for a larger share of the market due to the growing requirement for organ transplants and technological advancements in these devices.
Report Attribute | Details |
---|---|
3D Bioprinting Market Size (2022E) |
US$ 1.9 Bn |
Projected Market Value (2032F) |
US$ 8 Bn |
Global Market Growth Rate (2022-2032) |
15% CAGR |
Value Share of North America (2022A) |
31% |
“Increased Demand from Healthcare Industry for 3D Bioprinting”
In recent years, there has been an increased demand for 3D bioprinting in the healthcare sector around the world. These solutions are used for the development of organs and the construction of tissues, which are further used to develop medical implants and for R&D activities related to drugs.
The 3D bioprinting market is at an embryonic stage and this is used to generate a replacement for human tissue, which is estimated to result in a pioneer in the healthcare or medical vertical.
The technology is used for accurate and speedy drug testing due to its ability to test potential drug compounds on bioprinted tissues before being used on human beings.
“Growing Attention from Academicians on 3D Bioprinting”
3D bioprinting has been emerging as an area with increasing attention from academicians across the world. Several researchers have been opening start-up firms with the objective of commercialization of the technology in the years to come. Many start-ups are taking the initiative to build various products that are based on bioprinting technology.
“Presence of Key Market Players in North America”
Based on geographical analysis, North America is expected to hold a dominating position in the global market over the coming years. The dominance of the region is attributed to the increased count of the target population in North America.
The presence of key players and availability of sophisticated healthcare infrastructure in the region is also predicted to propel the growth opportunities in the North America 3D bioprinting market. In addition, increased investments by regional players in different R&D activities are also estimated to contribute to expansion opportunities in the market over the coming years.
The market at present has 14 industry sponsored bioprinters, focused on a variety of commercial applications. The widen supply-demand gap for organ transplants is an unmet need; the ultimate goal of researchers is to be able to create bioprinted organs for organ transplants.
The market of 3D bioprinting particularly focuses on commercial bioprinters and those under development, their applications and the expected future evolution. It is widely predicted that the 3D bioprinting market has great potential. It requires biocompatible materials (bio-ink and bio-paper), software (CAD), and hardware (bioprinters); each has the capability to grow into separate niche industries.
The focus of this market is expected to shift from research to commercialization. At this stage, the applications such as tissue engineering (skin and cartilage) and drug testing (skin and cartilage) are expected to be popular.
In coming years, 3D bioprinting to be a multi-billion dollar industry owning to the early success of bioprinted organ transplants is expected to offer an additional boost in subsequent years. The next generation of bioprinters is to offer additional features such as multiple arms and is expected to be comparatively more affordable driving wider adoption.
Aspect Biosystems would dramatically cut the cost and the time it takes to develop and test the drugs leading to cures for presently incurable diseases and cheaper treatment options. Companies in the bioprinting market include SkinPrint, which is developing a replacement skin for burn patients or for those suffering from skin disorders. Aspect Biosystems is developing printed tissue for drug testing.
Growing awareness about 3D bioprinting has increased competition among market players. some of the major players in the global 3D bioprinting market are Advanced Biomatrix, 3D Biotek, 3D Systems, Avita Medical, Bespoke Innovations, Autodesk, EnvisionTEC, Cyfuse Biomedical, CMC Microsystems, Digilab, United Therapeutics, TeVido BioDevices, DTM, Bio3D Technologies, Helisys Inc. CMC Microsystems, InSphero AG, and BD Biosciences, among others.
Leading players in the market are engaged in product innovation, research and development activities, and product launches and approval to maintain their position against their competitors. Apart from players, various institutions are also engaged in 3D bioprinting R&D.
Besides, Asia Pacific is also offering huge growth opportunities for the global 3D bioprinting market.
The 3D bioprinting market has been bifurcated on the basis of component, end user, application, and region.
Attribute |
Details |
---|---|
Forecast period |
2022-2032 |
Historical data available for |
2017-2021 |
Market analysis |
USD million for value |
Key regions covered |
|
Key countries covered |
|
Key market segments covered |
|
Key companies profiled |
|
Report Coverage |
|
Customization & pricing |
Available upon request |
By Component:
By Application:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The global market for 3D bioprinting is valued at US$ 1.9 Bn in 2022.
The global 3D bioprinting market is forecasted to expand at a high-value CAGR of 15% through 2032.
North America, owing to sophisticated healthcare infrastructure and increased R&D activities, leads the market with 31% revenue share.
Owing to technological advancements and rising demand for organ transplants, sales of 3D bioprinters are increasing steadily.